All In Biotech

Drug Trial Radar · NCT07239947

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and AD Patient

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Aug 9, 2025

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Bambusa TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • BBT001Drug

    BBT001 will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events following single and multiple administration of BBT001Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  2. Number of participants with change in vital sign measurements following treatment administration.Time frame: Part A- Up to Day 141; Part B-Up to Day 169 post first dose administration
  3. Number of participants with change in serum blood parameters.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  4. Number of participants with change in physical examination following treatment administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  5. Number of participants with change in 12-lead electrocardiogram (ECG) results measurements following treatment administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical Univesity

    Hefei, Anhui, China · Recruiting

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China · Not yet recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Wuxi Second People's Hospital

    Wuxi, Jiangsu, China · Not yet recruiting

  • Jiangsu University Affiliated Hospital

    Zhenjiang, Jiangsu, China · Not yet recruiting

  • Jiangxi Provincial Dermatology Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • Shandong Provincial Hospital for Skin Diseases

    Jinan, Shandong, China · Not yet recruiting

  • Shanghai Dermatology Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.